Holen Sie sich die Stockscreener-App
2.53
4.12%
0.10
Handel nachbörslich:
2.52
-0.010
-0.40%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.43
Offen:
$2.43
24-Stunden-Volumen:
7.60M
Relative Volume:
1.65
Marktkapitalisierung:
$510.11M
Einnahmen:
$116.33M
Nettoeinkommen (Verlust:
$-209.25M
KGV:
-1.1934
EPS:
-2.12
Netto-Cashflow:
$-135.49M
1W Leistung:
+14.48%
1M Leistung:
+69.80%
6M Leistung:
+42.94%
1J Leistung:
+39.01%
1-Tages-Spanne:
$2.395
$2.58
1-Wochen-Bereich:
$2.09
$2.58
52-Wochen-Spanne:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Firmenname
Esperion Therapeutics Inc
Sektor
Telefon
734-887-3903
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Vergleichen Sie ESPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.53 | 467.76M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
153.20 | 67.75B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.29 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.84 | 43.70B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.48 | 21.51B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
380.47 | 18.31B | 2.99B | 1.21B | 1.13B | 25.06 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-18 | Eingeleitet | Goldman | Neutral |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-01 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Hochstufung | BofA Securities | Underperform → Buy |
| 2023-03-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Fortgesetzt | BofA Securities | Neutral |
| 2023-02-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-19 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-09 | Herabstufung | Goldman | Neutral → Sell |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-10 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Underweight |
| 2020-08-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-24 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-16 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Hochstufung | Goldman | Sell → Neutral |
| 2019-03-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Bestätigt | Needham | Strong Buy |
| 2018-12-13 | Eingeleitet | Goldman | Sell |
| 2018-10-29 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-07-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
Alle ansehen
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
Is this a good reentry point in Esperion Therapeutics Inc.Market Activity Recap & Proven Capital Preservation Tips - Newser
Market reaction to Esperion Therapeutics Inc.’s recent newsShare Buyback & AI Enhanced Market Trend Forecasts - Newser
Combining machine learning predictions for Esperion Therapeutics Inc.July 2025 Outlook & Daily Volume Surge Signals - Newser
Esperion Therapeutics Inc. stock chart pattern explained2025 Bull vs Bear & High Return Trade Opportunity Guides - Newser
Real time pattern detection on Esperion Therapeutics Inc. stockPortfolio Value Summary & Growth Focused Stock Pick Reports - Newser
Will Esperion Therapeutics Inc. benefit from macro trendsJuly 2025 Institutional & Intraday High Probability Alerts - Newser
Tools to monitor Esperion Therapeutics Inc. recovery probabilityJuly 2025 Reactions & Fast Exit/Entry Strategy Plans - Newser
Published on: 2025-09-03 04:01:00 - Newser
Technical analysis overview for Esperion Therapeutics Inc. stockWeekly Trade Summary & Weekly High Return Forecasts - Newser
Candlestick signals on Esperion Therapeutics Inc. stock todayWeekly Trend Summary & AI Forecasted Stock Moves - Newser
What institutional flow reveals about Esperion Therapeutics Inc.Wall Street Watch & Safe Swing Trade Setups - Newser
Is Esperion Therapeutics Inc. benefiting from innovation trendsQuarterly Profit Review & AI Powered Buy/Sell Recommendations - khodrobank.com
Using flow based indicators on Esperion Therapeutics Inc.2025 Momentum Check & Expert Curated Trade Ideas - Newser
Using Bollinger Bands to evaluate Esperion Therapeutics Inc.Quarterly Risk Review & Safe Capital Growth Stock Tips - Newser
Published on: 2025-09-02 13:26:49 - Newser
Is Esperion Therapeutics Inc. stock ready for a breakout2025 EndofYear Setup & Accurate Entry and Exit Point Alerts - Newser
Can Esperion Therapeutics Inc. keep up with sector leadersOil Prices & Weekly Setup with High ROI Potential - khodrobank.com
Movement Recap: Can Esperion Therapeutics Inc. scale operations efficientlyGap Down & Real-Time Chart Pattern Alerts - khodrobank.com
Esperion rises after revenue beat, Q1 profitability expectation - MSN
Using data tools to time your Esperion Therapeutics Inc. exit2025 Institutional Moves & Accurate Trade Setup Notifications - Newser
Published on: 2025-09-01 19:45:56 - Newser
Is Esperion Therapeutics Inc. forming a bullish divergenceJuly 2025 Institutional & Pattern Based Trade Signal System - khodrobank.com
Should you hold or exit Esperion Therapeutics Inc. nowJuly 2025 Reactions & Free Growth Oriented Trading Recommendations - Newser
Analyzing Esperion Therapeutics Inc. with risk reward ratio chartsProduct Launch & Fast Entry Momentum Alerts - Newser
Published on: 2025-09-01 01:32:54 - Newser
Chart based analysis of Esperion Therapeutics Inc. trendsIndex Update & Fast Momentum Entry Tips - Newser
Using data models to predict Esperion Therapeutics Inc. stock movement2025 Valuation Update & AI Powered Market Trend Analysis - Newser
Heatmap analysis for Esperion Therapeutics Inc. and competitorsEarnings Overview Report & Safe Investment Capital Preservation Plans - Newser
Signal strength of Esperion Therapeutics Inc. stock in tech scannersMarket Growth Report & Fast Momentum Entry Tips - Newser
Will a bounce in Esperion Therapeutics Inc. offer an exitWeekly Loss Report & Risk Adjusted Swing Trade Ideas - Newser
Understanding Esperion Therapeutics Inc.’s price movementJuly 2025 Decliners & Momentum Based Trading Signals - Newser
Reversal indicators forming on Esperion Therapeutics Inc. stockMarket Sentiment Review & Growth Focused Investment Plans - Newser
Esperion Therapeutics Inc. stock trendline breakdownWeekly Trend Recap & Smart Money Movement Tracker - Newser
Analyzing recovery setups for Esperion Therapeutics Inc. investorsOil Prices & Growth Focused Stock Reports - Newser
Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Esperion Therapeutics Inc-Aktie (ESPR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Halladay Benjamin | Chief Financial Officer |
Jul 17 '25 |
Sale |
1.11 |
11 |
12 |
474,462 |
3.60%
0.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):